The National Institute for Health and Clinical Excellence (NICE) has complied with a Court of Appeal ruling and reconsidered the evidence for preventing fractures in patients with osteoporosis.
The original court ruling found the NICE had failed to fully explain its decision on a specific analysis of hip fractures from a research study carried out by the manufacturer of strontium ranelate (Protelos®). The actual recommendations were not questioned by the court. The court ruled that NICE must reconsider and reissue the guidance.
NICE has now reissued the osteoporosis - primary prevention and osteoporosis - secondary prevention including strontium ranelate. The guidelines are unchanged after the review.
Action: Clinicians should be aware that these guidelines are now published and implement any necessary changes to practice.
|« NSAID and PPI combination launched||Vascular benefits of statins and CRP »|